Research Square · Oct 22, 2026

Metformin use and the risk of gastric cancer: a systematic review and meta-analysis

By Wang Y, Sun D, Pan Z et al.

The use of metformin may reduce the risk of gastric cancer in people with type 2 diabetes, but the evidence remains controversial. We conducted a systematic review and meta-analysis to evaluate this association based on observational cohort studies. We systematically searched the PubMed, Embase, and Web of Science databases, covering the period from the inception of each database through December 2025. A total of 9 retrospective cohort studies involving 1,271,266 participants were included. Analysis using a random-effects model showed that metformin use was associated with a significant reduction in the risk of gastric cancer (HR = 0.72; 95% CI: 0.39–0.87; P = 0.0008). Subgroup analyses indicated no significant difference in the protective effect between genders; however, a significant risk reduction was observed only among those with long-term use (≥ 3 years) (HR = 0.30; 95% CI: 0.12–0.75), while short-term use (< 3 years) did not show a significant benefit. There was heterogeneity among the included studies (I² = 86%, P < 0.00001). These results suggest that metformin use, particularly long-term use, is associated with a reduced risk of gastric cancer in patients with type 2 diabetes. Given the heterogeneity among studies and potential publication bias, further high-quality prospective studies are needed to validate these findings before recommending metformin for the chemoprevention of gastric cancer.

doi.org/10.21203/rs.3.rs-11209422/v1Open accessInterventions

AgingResearch.News